NCT07531693 Patient Relevant Outcomes Improvement Program in High Risk Hormone Receptor Positive (HR+) Breast Cancer
| NCT ID | NCT07531693 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Institut fuer Frauengesundheit |
| Condition | HR+/HER2- Early Breast Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2026-02-19 |
| Primary Completion | 2026-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2026-02-19 with a primary completion date of 2026-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to evaluate how persistently patients with high-risk early breast cancer take abemaciclib 6 months after therapy start. To this end, researchers will perform a retrospective analysis of therapy data.
Eligibility Criteria
Inclusion Criteria: * Femal patients age 18 or older at time of informed consent * Confirmed diagnosis of HR+/HER2- early breast cancer (no distant metastasis) * Prescribed abemaciclib therapy according to the Summary of Product Characteristics (SmPC) * Abemaciclib therapy occured between January 1st, 2023 and June 30th, 2025 Exclusion Criteria: * Locally advanced or metastatic breast cancer * Male patients * Patients with contraindication(s) for abemaciclib therapy according to SmPC
Contact & Investigator
Peter A. Fasching, Prof. Dr. med.
STUDY CHAIR
Department of Obstetrics and Gynaecology, Uniklinikum Erlangen
Frequently Asked Questions
Who can join the NCT07531693 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying HR+/HER2- Early Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07531693 currently recruiting?
Yes, NCT07531693 is actively recruiting participants. Contact the research team at studien@ifg-erlangen.de for enrollment information.
Where is the NCT07531693 trial being conducted?
This trial is being conducted at Erlangen, Germany.
Who is sponsoring the NCT07531693 clinical trial?
NCT07531693 is sponsored by Institut fuer Frauengesundheit. The principal investigator is Peter A. Fasching, Prof. Dr. med. at Department of Obstetrics and Gynaecology, Uniklinikum Erlangen. The trial plans to enroll 200 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.